ENANTA PHARMACEUTICALS, INC
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-19.5M | $-13.1M | $-11.9M | $-18.7M | $-18.3M | $-22.6M | $-22.3M | $-28.8M |
| Depreciation & Amortization | $1.2M | $1.2M | $1.2M | $1.3M | $1.2M | $1.2M | $889.0K | $479.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.7M | $3.7M | $3.8M | $4.0M | $4.2M | $4.7M | $5.7M | $7.7M |
| Net Cash from Operating Activities | $-10.0M | $-7.2M | $-11.7M | $-6.5M | $17.5M | $-13.5M | $-16.8M | $-10.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $7.0K | $15.0K | $143.0K | $1.5M | $155.0K | $2.5M | $8.7M | $9.0M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $14.0M | $11.9M | $-47.3M | $2.3M | $-26.5M | $-4.4M | $68.9M | $19.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-5.5M | $-7.3M | $64.1M | $-8.3M | $-6.4M | $-6.9M | $-5.0M | $-7.2M |
| Net Change in Cash | $-1.5M | $-2.5M | $5.1M | $-12.5M | $-15.4M | $-24.7M | $47.1M | $1.5M |
| Free Cash Flow | $-10.0M | $-7.2M | $-11.8M | $-7.9M | $17.4M | $-16.0M | $-25.5M | $-19.4M |